BTG

Because people depend on us

Contact Us

Media

Utilities: Print; Email

Email to a friend

* Required

Press Releases

Please find below a list of our press releases, organised in chronological order.

20 February 2012 BTG to present at the Citi Global Health Care Conference
14 February 2012 BTG plc: Directorate Change Amendment
30 January 2012 BTG Announces Positive Data from First US Phase III Trial of Varisolve^®
25 January 2012 BTG plc: Interim Management Statement
18 January 2012 BTG plc: Voraxaze^® (glucarpidase) receives US regulatory approval
11 January 2012 BTG to present at the 30th Annual J.P. Morgan Healthcare Conference

07 December 2011 BTG plc: Voraxaze^® (glucarpidase) licensed to Ohara Pharmaceuticals in Japan
17 November 2011 BTG plc: Interim Results
11 November 2011 BTG plc: Garry Watts to succeed Dr John Brown as non-executive Chairman
01 November 2011 BTG plc: Directorate Change
05 October 2011 BTG plc: Close Period Update
20 September 2011 BTG plc: FDA accepts Biologics License Application file for Voraxaze^® (glucarpidase) and grants Priority Review
07 September 2011 BTG plc: ZYTIGA^™ (abiraterone acetate) approved in the EU
20 July 2011 BTG plc: Annual General Meeting and Interim Management Statement
11 July 2011 BTG plc: Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada^™) in Multiple Sclerosis Reported
06 July 2011 BTG Acquires US Marketing Rights to Wellstat’s Investigational Antidote for 5-FU Overexposure
25 May 2011 BTG plc: Final Results
13 May 2011 BTG plc: AstraZeneca ends CM-3 development and option agreement
03 May 2011 BTG plc: ZYTIGA^™ (abiraterone acetate) Approved in the US
05 April 2011 BTG plc: Close Period Update
11 March 2011 BTG plc: DEFEND-1 study of otelixizumab in type 1 diabetes did not meet primary endpoint
28 January 2011 Offer Update: Admission of New BTG Shares
27 January 2011 Offer Update: Scheme Effective
27 January 2011 BTG plc: Interim Management Statement
24 January 2011 Offer Update: Court sanction of the Scheme of Arrangement and timetable update
06 January 2011 Offer Update: Result of BTG Shareholder Meeting
06 January 2011 BTG to present at the J.P. Morgan Annual Healthcare Conference

21 December 2010 BTG plc: New Drug Application Submitted in the US and Marketing Authorisation Application Filed in the EU for Abiraterone Acetate
10 December 2010 Offer update: Posting of Scheme Document
29 November 2010 BTG plc: Appointment of Non-executive Director
19 November 2010 Recommended acquisition by BTG plc of Biocompatibles International plc
04 November 2010 BTG plc: Interim Results
25 October 2010 BTG plc: AstraZeneca initiates Phase IIb study for AZD9773 (CytoFab^™) as a treatment for severe sepsis
15 October 2010 BTG plc: Genzyme reports positive data on alemtuzumab
16 September 2010 BTG plc: First Varisolve^® US Phase III Trial Initiated
10 September 2010 BTG plc: Abiraterone Acetate Meets Pre-Determined Criteria in Metastatic Prostate Cancer Study
31 August 2010 BTG plc: Agreement with Nycomed US Inc.
13 July 2010 BTG plc: Annual General Meeting and Interim Management Statement
21 May 2010 BTG plc: Preliminary Results
01 April 2010 BTG plc: Close Period Update
04 February 2010 BTG Receives First European Regulatory Approval for DigiFab^™
21 January 2010 BTG Commences Phase IIa Study of Pleneva^™ for Multiple Sclerosis
21 January 2010 BTG plc: Interim Management Statement

18 December 2009 BTG Licenses ReGel^® to Allergan for use in diseases of the eye
05 November 2009 BTG plc: Interim Results
24 September 2009 BTG plc: Campath^® Meets Primary Endpoint in Phase III Combination Therapy Trial for Chronic Lymphocytic Leukemia
28 August 2009 BTG Sells HySolv^™ Technology to Major Pharmaceutical Company
17 August 2009 BTG Collaborator Onyx Gains Approval to Progress Oncology Compound into Clinical Development
29 July 2009 BTG plc: AstraZeneca to Progress CytoFab^™ into Phase IIb Study
15 July 2009 BTG plc: Annual General Meeting and Interim Management Statement
14 May 2009 BTG plc: Preliminary Results
02 April 2009 BTG plc: Close Period Update
22 January 2009 BTG plc: Interim Management Statement

04 December 2008 BTG plc: Completion of the Acquisition of Protherics PLC
20 November 2008 BTG Licensee Cougar Biotechnology Initiates Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Breast Cancer
12 November 2008 BTG plc: Interim Results for the Six Months Ended 30 September 2008
07 November 2008 Full Results of Varisolve^® US Phase II Safety Study to be Presented at ACP
07 November 2008 BTG licenses novel anticancer compound to Onyx Pharmaceuticals
05 November 2008 BTG plc: Result of EGM
28 October 2008 BTG plc to Announce its Interim Results on 12 November 2008
23 October 2008 BTG plc: Final Phase II Results of Campath^® Multiple Sclerosis Study Published
17 October 2008 BTG plc ("BTG") and Protherics PLC ("PROTHERICS"): Offer Update - Intended Date of Posting of Offer Documents
17 October 2008 BTG plc ("BTG") and Protherics PLC ("PROTHERICS"): Offer Update - Posting of Scheme Document/Receipt of Letters of Intent
18 September 2008 18 September 2008: Recommended All Share Offer by BTG plc for Protherics plc
06 August 2008 BTG plc: Tolerx Initiates Dosing of Otelixizumab in a Phase III Clinical Trial in Type 1 Diabetes
22 July 2008 BTG plc: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer
16 July 2008 BTG plc: Annual General Meeting and Interim Management Statement
06 June 2008 BTG Reports Successful Completion of Treatments in Varisolve^® US Phase II Safety Study
04 June 2008 BTG plc: Acquisition of Protez Pharmaceuticals by Novartis
19 May 2008 BTG plc: Preliminary Results for the Year Ended 31 March 2008
10 April 2008 BTG Reports Positive Results from First Study Investigating BGC20-0166 in Obstructive Sleep Apnoea Patients
02 April 2008 BTG plc: Close Period Update
17 March 2008 BTG plc: Positive Interim Report of Varisolve^® Phase II Safety Study to be Presented at SIR 2008 Scientific Meeting
06 March 2008 BTG Initiates Clinical Study of Novel Multiple Sclerosis Treatment
30 January 2008 BTG plc Commences First Clinical Study of Novel Migraine Treatment
24 January 2008 BTG plc: Interim Management Statement
17 January 2008 Senexis Raises £3.7 Million from the Wellcome Trust and BTG to Further Develop its Small Molecule Alzheimer's Compounds

13 December 2007 BTG Completes Enrolment of Phase II Clinical Trial of BGC20-0582 for Head Lice Infestation
04 December 2007 BTG plc Appoints Dr John Brown as Chairman Designate
07 November 2007 BTG plc: Interim Results for the Six Months Ended 30 September 2007
24 October 2007 BTG Licensee Tolerx Forms Collaboration with GlaxoSmithKline to Develop and Commercialise TRX4
28 September 2007 BTG plc: Board Changes
28 September 2007 BTG plc: Close Period Update
26 September 2007 BTG plc: Campath^® commences pivotal phase III trial in multiple sclerosis
20 September 2007 BTG plc: Campath^® approved for first-line use in Adult Leukemia
18 July 2007 BTG plc: 2007 Annual General Meeting and Interim Management Statement
07 June 2007 BTG plc: Orphan Drug Status Granted for Anticancer Drug Plevitrexed
25 May 2007 Preliminary Results Statement
19 April 2007 BTG Signs Agreement with Novacea and KuDOS for AQ4N
13 April 2007 BTG Continues Physical Sciences Divestment Programme Granting Two Licenses to Technology Patents Worth Up to $46m
02 April 2007 BTG plc: Close Period Update
27 February 2007 BTG Licensee Cougar Biotechnology Presents Positive Data on Prostate Cancer Compound at ASCO Symposium
20 February 2007 BTG Acquires Novel Opioid Agonist for Post-Operative Pain Control from CLL Pharma
19 February 2007 New Chief Medical Officer for BTG
22 January 2007 BTG's Plevitrexed Shows Promising Efficacy and Tolerability in a Phase I/II study

22 December 2006 BTG licenses haemofiltration device patents to Fresenius Medical Care
13 December 2006 Results of European Phase III Randomised Controlled Trial Comparing Varisolve ^® with Surgery or Sclerotherapy Published in Phlebology
12 December 2006 Genzyme reports Phase III data showing Campath^® is superior to Chlorambucil as a first-line therapy in B-CLL
09 November 2006 BTG plc: Interim Results for the Six Months Ended 30 September 2006
17 October 2006 Strata Technology Partners Retained by BTG to Auction Rights to a Substantial OLED Patent Portfolio
27 September 2006 BTG Appoints Peter Chambré as Non-Executive Director
25 September 2006 BTG Completes Sale of RFID Patent Portfolio
17 August 2006 BTG Licensee TolerRx, Inc. Raises $35.6m to Develop TRX4; Phase III Pivotal Trial in Type 1 Diabetes Planned to Commence in 2006
16 August 2006 BTG Sells Online Navigation Tracking Patents
31 July 2006 BTG PLC: Notification of Major Interests in Shares
26 July 2006 BTG plc: Results of AGM
26 July 2006 BTG plc: 2006 AGM Statement
25 July 2006 BTG plc: Notification of Major Interests in Shares
17 July 2006 BTG PLC: Notification of Major Interests in Shares
12 July 2006 Annual Information Update 2006
04 July 2006 BTG PLC: Notification of Major Interests in Shares
28 June 2006 Directors' Interests in the Shares of BTG plc
27 June 2006 BTG PLC: Application to the London Stock Exchange
23 June 2006 Notification of Submission of Documents to the UK Listing Authority
19 June 2006 Directors’ Interests in the Shares of BTG plc
19 June 2006 BTG to commence US phase II clinical safety study of Varisolve®
05 June 2006 BTG PLC : Notification of Major Interests in Shares
25 May 2006 BTG reports preliminary results for the year ended 31 March 2006
08 May 2006 BTG plc: Notification Of Major Interests In Shares
31 March 2006 BTG plc: Close Period Update
31 March 2006 BTG Sells Teleshuttle Patent Rights To Twintech E.U.
03 March 2006 BTG PLC : Notification of Major Interests in Shares
10 February 2006 BTG Appoints Piper Jaffray as Joint Financial Adviser and Joint Broker
06 February 2006 BTG Grants QRSciences Option to Acquire NQR Patents
02 February 2006 BTG Licenses Alzheimer's Compounds To Senexis And Co-Invests
£1 Million With The Wellcome Trust
27 January 2006 BTG Licenses Analgesic Compounds from Asterand

15 December 2005 BTG Initiates Proof of Mechanism Clinical Study for its Novel Drug Therapy for Obstructive Sleep Apnoea
24 November 2005 Directors' Interests in the Shares of BTG plc
17 November 2005 Directors' Interests in the shares of BTG plc
10 November 2005 BTG plc: Interim Results
07 November 2005 BTG plc Releases Financial Statement Information For The Year to 31 March 2005 Restated Under IFRS
10 October 2005 BTG Licenses Barnes & Noble to its Online Navigation Tracking Patents
03 October 2005 BTG plc: Close Period Update and sale of RFID patents
19 September 2005 BTG plc: Campath^® Progress and Date for Interim Results and Pipeline Update
05 September 2005 BTG PLC: Notification of Major Interests in Shares
29 August 2005 BTG and Collegium Pharmaceutical to Develop a Modified Release Asthma Product
15 August 2005 BTG Licenses Fundamental Online Navigation Tracking Patents to Netflix
28 July 2005 BTG PLC: 2005 Annual General Meeting
13 July 2005 BTG plc: Varisolve^{^®} given FDA approval to recommence US clinical trials
04 July 2005 Directors' Interests in the shares of BTG plc
28 June 2005 BTG plc: Notification of Submission of Documents to the UK Listing Authority
28 June 2005 Notification of Submission of Documents to the UK Listing Authority
24 June 2005 BTG plc: Publication of positive data from TRX4 type 1 diabetes study
26 May 2005 Directors' Interests in the shares of BTG plc
26 May 2005 BTG plc appoints Christine Soden as Chief Financial Officer
26 May 2005 BTG plc: Preliminary Results and Strategic Review
26 May 2005 BTG presents a live audio webcast to announce Preliminary results for the year ended 31 March 2005
23 May 2005 BTG PLC: Notification of Major Interests in Shares
19 May 2005 BTG settles two-part hip cup litigation
11 May 2005 BTG PLC: Notification of Major Interests in Shares
10 May 2005 BTG plc: Close Period Statement - Update
28 April 2005 BTG PLC : Notification of Major Interests In shares
21 April 2005 BTG plc: Update on Varisolve^{^®}
07 April 2005 BTG PLC: Notification of Major Interests in Shares
01 April 2005 BTG plc: CLOSE PERIOD UPDATE
09 February 2005 Statement regarding share price movement
27 January 2005 Update on Varisolve^{^®}

22 December 2004 Notification of major interests in shares
21 December 2004 Notification of Director's purchase of shares
15 December 2004 Notification of major interests in shares
13 December 2004 KetoCytonyx reports positive Phase I study of neuroprotectant
13 December 2004 Notification of Directors' purchase of shares
08 December 2004 Business Update
06 December 2004 Notification of major interest in shares
01 December 2004 BTG Licenses the Electro-Absorption Modulator and Distributed FeedBack Laser Technologies to Mitsubishi Electric
11 November 2004 Directors' Interests in the shares of BTG plc
11 November 2004 BTG plc: Interim results
10 November 2004 BTG presents a live audio webcast to announce interim results for the six months ended 30 September 2004
08 November 2004 BTG Seeks Exclusive Licensee for a Fundamental Technology on Transparent Cathodes in Polymer OLED Devices
04 October 2004 BTG plc: Close period update and notice of results
30 September 2004 Varisolve^{^®} update
28 September 2004 BTG Establishes Collaboration Agreement with Collegium Pharmaceutical to Develop Innovative Therapy for Sleep Apnoea
28 September 2004 BTG Announces Licensing and Research Agreement with the University of Illinois at Chicago to Develop Novel Therapy for Treatment of Sleep Apnoea
16 September 2004 BTG plc Appoints Louise Makin as Chief Executive Officer
15 September 2004 BTG Sues Amazon.com, BarnesandNoble.com, Netflix and Overstock.com for Infringement of Patents for Online Navigation Tracking Technologies
13 September 2004 Statement Regarding Share Price Movement
07 September 2004 BTG plc appoints Alison Wood to the Board
29 July 2004 Notification of Major Interests in Shares
29 July 2004 BTG to Commercialise Conductive Keratoplasty^{^®} Patents
28 July 2004 BTG PLC : RESULTS OF 2004 ANNUAL GENERAL MEETING
28 July 2004 BTG plc: 2004 AGM Statement
20 July 2004 BTG and Teleshuttle Sue Microsoft for Infringement of Patents for Active Desktop and Offline Browsing Technologies
20 July 2004 BTG and Teleshuttle Sue Microsoft and Apple for Infringement of Patent for Online Software Updates
07 July 2004 KetoCytonyx Commences Phase I Study for Neuroprotectant KTX 0101
25 June 2004 BTG PLC : NOTIFICATION OF MAJOR INTERESTS IN SHARES
27 May 2004 Notification of Major Interests in Shares
27 May 2004 BTG plc: Preliminary results for the year ended 31 March 2004
26 May 2004 BTG presents a live audio webcast to announce Preliminary results for the year ended 31 March 2004
19 May 2004 BTG Takes Exclusive Licence to New Class of Cancer Drug from Cancer Research Technology and The Institute of Cancer Research
17 May 2004 BTG Strengthens Non-Invasive Prenatal Diagnostic Technology Patent Portfolio
17 May 2004 BTG PLC : NOTIFICATION OF MAJOR INTERESTS IN SHARES
10 May 2004 BTG Announces High Structural Fidelity in Lewis P450 Model
04 May 2004 BTG Strengthens Drug Portfolio in Diseases of Ageing
27 April 2004 BTG Announces Availability of a Novel Chalcogenide Laser for License
20 April 2004 BTG Licenses New Prostate Cancer Drug to Cougar Biotechnology
14 April 2004 BTG and Corning Announce Representation Agreement to License Fundamental Optics Patents
01 April 2004 BTG PLC : NOTIFICATION OF MAJOR INTERESTS IN SHARES
01 April 2004 BTG plc: CLOSE PERIOD UPDATE AND NOTICE OF RESULTS
29 March 2004 DIRECTORS' INTERESTS IN SHARES
29 March 2004 BTG Appoints Fulcrum Pharma as its Preferred Provider of Drug Development Services
26 March 2004 NOTIFICATION OF CHANGE IN DIRECTORS’ SHAREHOLDINGS
24 March 2004 BTG PLC : NOTIFICATION OF MAJOR INTERESTS IN SHARES
23 March 2004 Result of Rights Issue
23 March 2004 BTG and DxS Sign Exclusive Licence with AstraZeneca to Commercialise ARMS^™ DNA Diagnostic Technology
15 March 2004 BTG PLC : NOTIFICATION OF MAJOR INTERESTS IN SHARES
02 March 2004 BTG PORTFOLIO COMPANY, VISIONTEC, ACQUIRED BY US RETAILER 1-800 CONTACTS INC
26 February 2004 BTG Announces Strategic Relationship with Irish BioVentures
24 February 2004 BTG Completes Series A Investment in Protez Pharmaceuticals Inc.
17 February 2004 BTG Backs Molecular Biology Chair at Leading Oxford Research Centre
12 February 2004 PROPOSED 2 FOR 5 RIGHTS ISSUE OF UP TO 42,165,208 RIGHTS ISSUE SHARES AT 70 PENCE PER SHARE
04 February 2004 BTG Announces Licensing Agreement with Gambro Renal Products for Hemofiltration Device Developed at Cincinnati Children’s Hospital
29 January 2004 Mesophotonics secures $10 million (£5.5m) in second round

Keep up to date

You can keep up to date with our news by subscribing to our email alerts. Alternatively keep up to date with changes to our website by subscribing to one of our news feeds.

Regulatory news

In addition to press releases we issue regulatory news to the London Stock Exchange.

Regulatory news